Scinai Immunotherapeutics Ltd. Annual Report - How They Did This Year

I’m writing this guide to help you understand Scinai Immunotherapeutics’ performance this year. My goal is to translate complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do and how did they perform?

Scinai is an Israeli biotech company with two main business lines:

• The R&D Engine: They develop biological drugs using "NanoAbs" (tiny antibodies). Their lead project, SCIN-11, targets inflammation and autoimmune conditions like plaque psoriasis.
• The CDMO Engine: This is their service business. They operate a high-tech facility in Jerusalem, helping other biotech firms develop and produce drugs. This generates cash to support their own research. In 2025, this segment brought in $0.4 million in revenue.

2. Financial performance: The "Going Concern" Warning

The most critical point is the "going concern" warning in their report. Auditors have expressed concern regarding the company's ability to continue as a going concern, as they must secure more cash through new shares, loans, or partnerships to sustain operations.

• Cash on hand: They held $1.6 million at the end of 2025, down from $1.9 million the previous year.
• Burning cash: The company lost $7.5 million in 2025. High research costs and facility maintenance drive these expenses. With a monthly burn rate of $0.5 million to $0.6 million, their cash will likely run out by mid-2026 without new funding.

3. Major wins and challenges this year

• The "Reverse Split": In May 2024, the company combined shares in a 1-for-10 ratio. Now, one American Depositary Share (ADS) represents 4,000 ordinary shares. This was a defensive move to keep their share price above the $1.00 minimum required by the Nasdaq.
• The Balancing Act: They are working to grow their service business to break even. Currently, the high cost of running their specialized facility outweighs the income from their clients.

4. Key risks that could hurt the stock price

• Survival and Dilution: Because they are losing money, they will likely issue more shares to raise cash. This reduces your ownership percentage and the value of your existing shares.
• Nasdaq Compliance: To stay listed, they must maintain at least $2.5 million in stockholders' equity. If they fail to meet this or the minimum share price, they risk being delisted. This would make it much harder to trade the stock and likely cause the price to drop.
• Operational and Geopolitical Risks: Their facility is in Jerusalem. The ongoing conflict in Israel creates risks for their supply chain, staff availability, and physical safety. A prolonged shutdown would stop both their research and their ability to serve clients.

Final Thought for Investors: Scinai is currently in a high-stakes phase. Their investment appeal rests on whether they can secure the necessary funding to survive the next 12 months while simultaneously scaling their CDMO service business to generate enough revenue to cover their research costs. If you are considering an investment, keep a close eye on their cash balance and any announcements regarding new financing or partnerships.